AZN vs. IRTC: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AZN and IRTC, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN dominates in value with a market cap of 432.07 billion USD, eclipsing IRTC’s 4.47 billion USD by roughly 96.76×.
IRTC carries a higher beta at 1.34, indicating it’s more sensitive to market moves, while AZN remains steadier at 0.18.
AZN trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while IRTC remains a standard domestic listing.
| Symbol | AZN | IRTC |
|---|---|---|
| Company Name | AstraZeneca PLC | iRhythm Technologies, Inc. |
| Country | GB | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| CEO | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | Mr. Quentin S. Blackford |
| Price | 69.68 USD | 139.87 USD |
| Market Cap | 432.07 billion USD | 4.47 billion USD |
| Beta | 0.18 | 1.34 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 12, 1993 | October 20, 2016 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of AZN and IRTC over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of AZN and IRTC based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- IRTC shows a negative P/E of -44.94, highlighting a year of losses, whereas AZN at 27.80 trades on solid profitability.
- IRTC shows a negative forward PEG of -3.27, signaling expected earnings contraction, while AZN at 2.50 maintains analysts’ projections for stable or improved profits.
| Symbol | AZN | IRTC |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.80 | -44.94 |
| Forward PEG Ratio (TTM) | 2.50 | -3.27 |
| Price-to-Sales Ratio (P/S, TTM) | 3.93 | 7.22 |
| Price-to-Book Ratio (P/B, TTM) | 5.26 | 50.98 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.33 | 320.26 |
| EV-to-EBITDA (TTM) | 13.68 | -68.66 |
| EV-to-Sales (TTM) | 4.41 | 7.80 |
| EV-to-Free Cash Flow (TTM) | 25.07 | 346.10 |
Dividend Comparison
AZN delivers a 1.39% dividend yield, blending income with growth, whereas IRTC appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.
| Symbol | AZN | IRTC |
|---|---|---|
| Dividend Yield (TTM) | 1.39% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AZN and IRTC, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 signals a possible liquidity squeeze, while IRTC at 5.71 comfortably covers its short-term obligations.
- AZN’s quick ratio of 0.70 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas IRTC at 5.58 maintains a comfortable buffer of liquid assets.
- IRTC is highly leveraged (debt-to-equity ratio 8.49), elevating both potential gains and risks, compared to AZN at 0.77, which maintains a steadier capital structure.
- AZN meets its interest obligations (ratio 7.95). In stark contrast, IRTC’s negative ratio (-16.44) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
| Symbol | AZN | IRTC |
|---|---|---|
| Current Ratio (TTM) | 0.90 | 5.71 |
| Quick Ratio (TTM) | 0.70 | 5.58 |
| Debt-to-Equity Ratio (TTM) | 0.77 | 8.49 |
| Debt-to-Assets Ratio (TTM) | 0.30 | 0.79 |
| Interest Coverage Ratio (TTM) | 7.95 | -16.44 |